ProShares Ultra NASDAQ Biotechnology
19 hedge funds and large institutions have $2.55M invested in ProShares Ultra NASDAQ Biotechnology in 2025 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 1 increasing their positions, 4 reducing their positions, and 4 closing their positions.
57% more capital invested
Capital invested by funds: $1.62M → $2.55M (+$927K)
50% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 4
12% more funds holding
Funds holding: 17 → 19 (+2)
1.85% more ownership
Funds ownership: 3.47% → 5.32% (+1.9%)
75% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PWM
Palumbo Wealth Management
Great Neck,
New York
|
+$692K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$417K |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$278K |
| 4 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$43K |
| 5 |
PNC Financial Services Group
Pittsburgh,
Pennsylvania
|
+$26.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WWM
Westwood Wealth Management
Los Angeles,
California
|
-$366K |
| 2 |
TRCT
Tower Research Capital (TRC)
New York
|
-$110K |
| 3 |
PSFG
Park Square Financial Group
Roswell,
Georgia
|
-$14.5K |
| 4 |
GC
Garde Capital
Seattle,
Washington
|
-$10.8K |
| 5 |
CIA
Capital Investment Advisors
Atlanta,
Georgia
|
-$10.8K |
BIB Hedge Fund Activity: Q3 2025 in Review
19 of the 7,643 institutional investors tracked by Wall St. Rank reported a position in ProShares Ultra NASDAQ Biotechnology (BIB) for Q3 2025, worth a combined $2.55M — up 57% from $1.62M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new BIB positions and 4 closed out — a net gain of 2 holders — while 1 added to existing stakes and 4 trimmed.
The largest buyer was Palumbo Wealth Management, opening a new position worth an estimated $692K. The largest seller was Westwood Wealth Management, exiting entirely with an estimated $366K sold.
- 19 institutional investors held ProShares Ultra NASDAQ Biotechnology (BIB) as of Q3 2025, up from 17 in Q2 2025.
- Funds reported $2.55M of ProShares Ultra NASDAQ Biotechnology stock for Q3 2025, up 57% quarter-over-quarter.
- 6 funds opened new ProShares Ultra NASDAQ Biotechnology positions in Q3 2025 and 4 closed out, a net change of +2 holders.
- The largest ProShares Ultra NASDAQ Biotechnology buyer in Q3 2025 was Palumbo Wealth Management, an estimated $692K added.
- The largest ProShares Ultra NASDAQ Biotechnology seller in Q3 2025 was Westwood Wealth Management, an estimated $366K sold.
Based on aggregated 13F filings for Q3 2025.